Back to results
US 2022/0017614 A1Published application
Anti-IL6 Agent for Treating Coronavirus Infection
AssigneeJanssen Biotech, Inc.
InventorsKatia Boven, Jason Chien, Magda Opsomer, Brian Woodfall
Life of this patent
Estimating the term…
Abstract
An anti-IL6 agent that blocks binding of IL-6 to IL-6 receptor, for example, an anti-IL6 antibody comprising a heavy chain variable region of SEQ ID NO:99 and a light chain variable region of SEQ ID NO:97, is useful in the treatment or prevention of infection of a human with SARS-CoV-1 and/or SARS-CoV-2.
Claims35
A method for treating an infection of SARS-CoV-1 and/or SARS-CoV-2 in a human patient comprising administering to the patient an effective amount of a pharmaceutical composition comprising an anti-IL6 agent.
An isolated anti-IL6 antibody comprising:
- (i) a heavy chain variable region amino acid sequence of SEQ ID NO:99 and a light chain variable region amino acid sequence of SEQ ID NO:97;
- (ii) a CDRH1 a CDRH1 amino acid sequence SEQ ID NO:
- 39, a CDRH2 amino acid sequence of SEQ ID NO:
- 59, a CDRH3 amino acid sequence of SEQ ID NO:
- 89, a CDRL1 amino acid sequence of SEQ ID NO:
- 3, a CDRL2 amino acid sequence of SEQ ID NO:
- 21 and a CDRL3 amino acid sequence of SEQ ID NO:
- 29;
- or (iii) a CDRH1 amino acid sequence of SEQ ID NO:
- 39, a CDRH2 amino acid sequence of SEQ ID NO:
- 59, a CDRH3 amino acid sequence of SEQ ID NO:
- 89, a CDRL1 amino acid sequence of SEQ ID NO:
- 3, a CDRL2 amino acid sequence of SEQ ID NO:
- 21 and a CDRL3 amino acid sequence of SEQ ID NO:
- 29, for use in the treatment of infection of a human with SARS-CoV-1 and/or SARS-CoV-2.
12 more elements
Dependencies are inferred from the claim text.